PYLARIFY® PET/CT Case Studies


In patients with high-risk PCa who were candidates for initial definitive therapy, PYLARIFY® PET/CT identified extra-pelvic lesions in 12.3% of patients, which were not detected with conventional imaging2

Anterior and posterior diagnostic images of the human body

Bone Scan

Anterior and posterior diagnostic images of the human pelvis showing pelvic lesions

PET Image with PYLARIFY®

A patient in OSPREY with baseline staging T1c N0 M0, PSA 13.68 ng/mL, and Gleason score 4+5. CT imaging (not shown) showed no evidence of metastatic disease, and bone scintigraphy showed changes of left hip arthroplasty and increased tracer uptake in the anterior superior iliac spine (shown with arrow), but otherwise normal. PYLARIFY® (piflufolastat F 18) injection showed multifocal osseous lesions on the spine, ribs, pelvis, and right clavicle. Biopsy of left transverse process of L3 confirmed osseous metastatic disease (M1b).2

In CONDOR, across the 3 readers, PYLARIFY® detected at least 1 previously occult lesion in 59.6%-65.9% of patients3,4

Diagnostic images from the Condor Trial showing abdominal lesions in the human body Diagnostic images from the Condor Trial showing abdominal lesions in the human body
PYLARIFY® PET scan revealing that a 71-year-old patient had lesions in the left common iliac and lymph nodes PYLARIFY® PET scan revealing that a 71-year-old patient had lesions in the left common iliac and lymph nodes
  • 71-year-old patient had a Gleason score of 4+3, history of radical prostatectomy, EBRT with PSA 1.92 ng/mL, and equivocal results on 18F fluciclovine PET/CT scan
  • PYLARIFY® showed left common iliac lesions and multiple retroperitoneal para/peri aortic lymph node lesions
  • Biopsy of retroperitoneal lymph node confirmed prostate cancer

SEE SAFETY DATA
FOR PYLARIFY®

LEARN MORE

CT=computed tomography; EBRT=external beam radiation therapy; GnRH=gonadotropin-releasing hormone; MRI=magnetic resonance imaging; PCa=prostate cancer; PET=positron emission tomography; PSA=prostate-specific antigen.

IMPORTANT SAFETY
INFORMATION

Contraindications

None.

Warnings and Precautions

References

  1. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company
  2. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPYL in prostate cancer patients (OSPREY) [published online ahead of print, February 26, 2021]. J Urol. doi:10.1097/JU.0000000000001698
  3. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPYL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study [published online ahead of print, February 23, 2021]. Clin Cancer Res. doi:10.1158/1078-0432.CCR-20-4573
  4. Data on file. New York, NY: Progenics Pharmaceuticals, Inc.; 2021.